ACADIA Pharmaceuticals Inc.
ACAD
$20.84
$0.120.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.07B | 1.05B | 1.02B | 996.28M | 957.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.07B | 1.05B | 1.02B | 996.28M | 957.80M |
| Cost of Revenue | 417.80M | 429.35M | 405.34M | 401.12M | 385.09M |
| Gross Profit | 653.71M | 617.77M | 613.55M | 595.17M | 572.71M |
| SG&A Expenses | 548.89M | 523.36M | 523.25M | 506.81M | 488.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 966.69M | 952.71M | 928.59M | 907.92M | 873.52M |
| Operating Income | 104.81M | 94.41M | 90.30M | 88.36M | 84.28M |
| Income Before Tax | 138.90M | 273.67M | 267.88M | 264.85M | 258.08M |
| Income Tax Expenses | -252.10M | 12.50M | 45.72M | 35.97M | 31.62M |
| Earnings from Continuing Operations | 391.00 | 261.17 | 222.16 | 228.88 | 226.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 391.00M | 261.17M | 222.16M | 228.88M | 226.45M |
| EBIT | 104.81M | 94.41M | 90.30M | 88.36M | 84.28M |
| EBITDA | 116.57M | 108.46M | 103.97M | 101.67M | 100.16M |
| EPS Basic | 2.31 | 1.56 | 1.33 | 1.38 | 1.36 |
| Normalized Basic EPS | 0.52 | 0.47 | 0.45 | 0.45 | 0.42 |
| EPS Diluted | 2.29 | 1.55 | 1.33 | 1.37 | 1.36 |
| Normalized Diluted EPS | 0.51 | 0.47 | 0.45 | 0.44 | 0.42 |
| Average Basic Shares Outstanding | 672.81M | 670.01M | 667.14M | 664.87M | 662.86M |
| Average Diluted Shares Outstanding | 678.36M | 673.70M | 669.22M | 666.72M | 665.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |